Gilead, LEO Pharma partner to develop programs for inflammatory diseases
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...
Business Insider9h
Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD)
According to TipRanks, Breen has an average return of -6.2% and a 33.33% success rate on recommended stocks. In addition to Bernstein, Gilead Sciences also received a Buy from Morgan Stanley’s Terence ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
The stock's rise snapped a five-day losing streak.
SciDev1dOpinion
HIV drug access crisis persists despite trial success
Addressing stigma, inequity, and access to HIV innovations remains critical to progress in the global HIV response, says IAS ...
BioSpace2d
Galapagos to Spin Out Innovative Medicines, Lay Off 40%
By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...
BioSpace3d
Galapagos to Spin Out Innovative Medicines, Regain Gilead Assets
By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...
Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines ...